Gossamer Bio, Inc. filed a Certificate of Amendment to its Charter on September 10, 2026, effecting a 1-for-80 reverse stock split of its common stock and reducing authorized shares from 4 billion to 50 million. The transaction became effective at 11:59 p.m. Eastern Time on September 10, 2026, with split-adjusted trading commencing on the Nasdaq Global Select Market on September 11, 2026. Fractional shares are rounded up to the nearest whole share rather than being cashed out. Convertible notes and warrants were proportionately adjusted to reflect the new ratio. The company states this action is intended to help regain compliance with Nasdaq's minimum bid price requirement by October 5, 2026. Gossamer Bio operates in the biopharmaceutical industry, developing treatments for pulmonary hypertension.

Gossamer Bio announced that its board selected a 1-for-80 reverse stock split ratio for its common stock. The transaction is expected to become effective on September 10, 2026, at 11:59 p.m. Eastern Time, with split-adjusted trading beginning on the Nasdaq Global Select Market on September 11, 2026. This action aims to regain compliance with Nasdaq's minimum bid price requirement. Concurrently, authorized common shares will decrease from 4 billion to 50 million, and total authorized capital stock will reduce from 4.07 billion to 120 million. Fractional shares will be rounded up to the nearest whole share rather than paid in cash. The company is a clinical-stage biopharmaceutical firm developing seralutinib for pulmonary arterial hypertension.

Gossamer Bio filed a Certificate of Designation to establish Series A-1 Convertible Preferred Stock in connection with the closing of a previously announced private placement. This action amends the company's certificate of incorporation to define the preferences, rights, and limitations of this new equity class. Gossamer Bio operates as a clinical-stage biotechnology company focused on developing treatments for autoimmune diseases.

Gossamer Bio entered into a securities purchase agreement for a structured private placement with aggregate gross proceeds of up to $250 million. The initial closing, expected August 24, 2026, will generate approximately $25 million from pre-funded warrants priced at $0.1399 each. A second closing is committed upon FDA acceptance of the New Drug Application for seralutinib in pulmonary arterial hypertension, providing an additional $125 million. If the FDA approves seralutinib, investors may exercise FDA Approval Warrants to provide up to $100 million more. Proceeds will fund clinical development and operations into 2028. Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib for pulmonary arterial hypertension.

Gossamer Bio reported a net income of $16.9 million for Q2 2026, driven by a $43.8 million gain on debt extinguishment from exchanging approximately $115.9 million in convertible notes. The company reacquired worldwide rights to its lead drug seralutinib from Chiesi for a one-time $5 million payment and plans to submit an NDA for PAH in September 2026 following FDA feedback. Stockholders previously approved the note exchange and authorized a reverse stock split, though the specific ratio and effective date remain subject to Board approval. Cash reserves totaled $57.0 million as of June 30, 2026. Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary arterial hypertension.